Live Breaking News & Updates on Lecanemab

Stay informed with the latest breaking news from Lecanemab on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Lecanemab and stay connected to the pulse of your community

Alzheimer's trial brings at-risk patients hope for the future, but new doubts in the present

Could a new model of testing and drugs make this brain disease as treatable as Type 2 diabetes? As researchers run tests to find out, neuroscience is divided on what to do for now

Toronto , Ontario , Canada , Germany , Ottawa , Japan , United-states , United-kingdom , Amsterdam , Noord-holland , Netherlands , China

World Dementia Council seeks Alzheimer's action in next 10 years

Europe may still await its first disease-modifying Alzheimer’s drug after the EMA postponed its decision on Leqembi (lecanemab, Biogen Inc./Eisai Co. Ltd) on March 22, but leading members of the World Dementia Council were in an optimistic mood when they convened in London four days later.

London , City-of , United-kingdom , Lenny-shallcross , World-dementia-council , Ltd-on , Biogen-inc-eisai-co , Biogen-inc , Biogen-inc- , Eisai-co-ltd- , Alzheimers-disease , Lecanemab

Is Alzheimer's the same as dementia? A brain expert explains

A breakthrough new drug to treat brain disease is always welcome news. Last summer, the performance of the drugs donanemab and lecanemab in clinical trials...

United-kingdom , Germany , German , Alois-alzheimer , David-cox , Regulatory-agency , Alzheimer-research-united-kingdom , Research-united-kingdom , Is , Alzheimers , The , Same

Aduhelm kaput in Alzheimer's, Biogen leans into Leqembi

Biogen Inc.’s problematic trip with Aduhelm (aducanumab-avwa) for Alzheimer’s disease at last came to an end as the company, probably surprising few on Wall Street, said it’s quitting sales and development of the amyloid-beta directed antibody. The drug won accelerated approval by the U.S. FDA in July 2021.

Cambridge , Cambridgeshire , United-kingdom , Biogen-inc , Wall-street , Aduhelm , Biogen-inc- , Leqembi , Aducanumab , Lecanemab , Alzheimers-disease

Aduhelm Went From Being Hailed A "Game Changer" To Becoming A Dud

Biogen announced it will discontinue marketing the Alzheimer’s drug Aduhelm. This ends the tortuous saga of a once-promising treatment for the memory-robbing disease.

Switzerland , New-york , United-states , Swiss , Drug-administration , New-york-times , Centers-for-medicare , Eli-lilly , Bloomberg , Clinical-trials-on-alzheimer-disease-congress , Clinical-trials

Controversial Alzheimer's drug Aduhelm is being discontinued, company says

Biogen will stop developing its Alzheimer's treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling after its launch a couple years ago.

Cambridge , Cambridgeshire , United-kingdom , Japan , Japanese , Biogen-inc , Drug-administration , Massachusetts-based-biogen , Massachusetts , United-states , Biogen-inc-

Biogen Discontinues Aducanumab for Alzheimer Disease

Biogen has officially announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease.

Zerbor-adobestock , George-vradenburg , Chris-viehbacher , Drug-administration , Eisai-partnered-leqembi , Alzheimer , Aducanumab , Lecanemab ,

'It's a gamechanger and reason for hope': neurologist describes new Alzheimer's drug

On Dec. 1, 2023, UNC Health Pardee became the first hospital in Western North Carolina to administer a dose of a new Alzheimer’s drug...

North-carolina , United-states , Hendersonville , Joel-callahan , Health-pardee , Western-north-carolina , Health-medical-pharma , S-callahan , Cognitive-disorders , Alzheimer-x27s-disease , Dementia , Lecanemab

'It's a gamechanger & it's a reason for hope,' neurologist describes new Alzheimer's drug

On Dec. 1, 2023, UNC Health Pardee became the first hospital in WNC to administer a dose of a new Alzheimer’s drug that has shown promising benefits.

North-carolina , United-states , Hendersonville , Joel-callahan , Health-pardee , Western-north-carolina , Health-medical-pharma , S-callahan , Groundbreaking-alzheimer , Aphasias , Dementia , Lecanemab

First dose of new Alzheimer's drug given in WNC, UNC Health Pardee announces

UNC Health Pardee says it's the first health care organization in Western North Carolina to administer a newly FDA-approved drug to treat Alzheimer's disease.

North-carolina , United-states , Hendersonville , Joel-callahan , Health-pardee , Pardee-neurology-associates , Western-north-carolina , Mayo-clinic , Health-medical-pharma , Groundbreaking-alzheimer , Pardee , Lecanemab